Success in trials of tardive dyskinesia treatment
I highlighted (Dec 2015) Teva’s SD-809 (deutetrabenazine) treatment for tardive dyskinesia. The disease causes uncontrollable movements in around 500,000 US patients. The second Phase III trial of the treatment produced statistically significant results.
This entry was posted in Israel's Medical Achievements
. Bookmark the permalink